Recruiting
Phase 1

LY4247147

Sponsor:

Eli Lilly and Company

Code:

NCT07915245

Conditions

Obesity

Overweight

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Not accepted

Interventions

LY4247147

LY4247147

Placebo

Study Details

Brief summary:

The main purpose of this study is to understand how safe and well-tolerated LY4247147 is in participants with obesity or overweight who are otherwise healthy. Blood tests will be performed to check how much LY4247147 gets into the bloodstream and how long it takes the body to eliminate it.

The study will be conducted in 3 parts. For each participant in Parts A and C, the study will last about 30 weeks and will include a stay in the Clinical Research Unit (CRU) lasting about 8 nights. For each participant in Part B, the study will last about 39 weeks and will include up to 3 stays in the CRU lasting about 9 nights each.

Conditions

Obesity

Overweight

Study ID

NCT07915245

Start date

Nov 6, 2026

Status verified date

Nov, 2026

Completion date

Oct, 2028

Anticipated

Primary completion date

Oct, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Are overtly healthy with no comorbidities related to body mass index (BMI), such as type 2 diabetes mellitus or unstable cardiovascular disease.
  • Have overweight with a BMI of greater than or equal to (≥) 27 kilograms per square meter (kg/m²).
  • Have obesity with a BMI of ≥30 kg/m2.
  • Have had a self-reported stable weight for 3 months prior to screening.
  • Singapore only: Participants must be 21 to 65 years of age.

Exclusion Criteria:

  • Have a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal (GI), endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs, or of constituting a risk when taking the study intervention, or of interfering with the interpretation of data.
  • Is an individual of childbearing potential (IOCBP).

Study Design

Enrollment

108 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: LY4247147 Part A

LY4247147 administered subcutaneously (SC)

placebo comparator: Placebo Part A

Placebo administered SC

experimental: LY4247147 Part B

LY4247147 administered SC

placebo comparator: Placebo Part B

Placebo administered SC

experimental: LY4247147 Part C

LY4247147 administered intravenously (IV)

Interventions

LY4247147

administered SC

LY4247147

administered IV

Placebo

administered SC

Primary outcome measure

  • Part A and C: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration [ Time Frame: Baseline through End of the Follow-up (Estimated as Week 25) ]
  • Part B: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration [ Time Frame: Baseline through End of the Follow-up (Estimated as Week 33) ]

Central Contacts and Locations

Central contacts

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or

1-317-615-4559LillyTrials@Lilly.com

Physicians interested in becoming principal investigators please contact

clinical_inquiry_hub@lilly.com

Locations

ICON Early Phase Services Lenexa Center

Recruiting

Lenexa, Kansas, United States, 66219

Contacts

Principal Investigator:

DANIEL DICKERSON

More Information

Sponsor

Eli Lilly and Company

Last update posted

Nov 18, 2026

Last verified

Nov, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-19. This information was provided to ClinicalTrials.gov by Eli Lilly and Company on 2026-11-18. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.